2256.HK Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 geg. 2024 @ 11:08):

Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, discovers and develops small molecule oncology therapies in the People's Republic of China...

Stats
Dzisiejszy wolumen	1.10M
Średni wolumen	1.72M
Kapitalizacja rynkowa	2.47B
EPS	HKD0 ( 2024-03-11 )
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-4.94
ATR14	HKD0.0160 (0.45%)

Wolumen Korelacja

Długi: -0.28 (neutral)

Krótki: 0.51 (weak)

Signal:(51.653) Neutral

Abbisko Cayman Limited Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Abbisko Cayman Limited Korelacja - Waluta/Towar

0.75
( moderate )

0.73
( moderate )

0.00
( neutral )

0.72
( moderate )

-0.16
( neutral )

-0.72
( moderate negative )

Abbisko Cayman Limited Finanse

Annual	2023
Przychody:	HKD19.06M
Zysk brutto:	HKD19.06M (100.00 %)
EPS:	HKD-0.670

FY	2023
Przychody:	HKD19.06M
Zysk brutto:	HKD19.06M (100.00 %)
EPS:	HKD-0.670

FY	2023
Przychody:	HKD0
Zysk brutto:	HKD0 (0.00 %)
EPS:	HKD0

FY	2022
Przychody:	HKD0
Zysk brutto:	HKD0 (0.00 %)
EPS:	HKD-0.800

Financial Reports:

No articles found.

Abbisko Cayman Limited

Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, discovers and develops small molecule oncology therapies in the People's Republic of China. Its product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. The company's primary product candidates are ABSK011, a small molecule inhibitor of fibroblast growth factor receptor 4 for the treatment of advanced hepatocellular carcinoma with hyper-activation of FGF19/FGFR4 signaling; and ABSK091, a molecularly targeted product candidate for the treatment of multiple solid tumors, including urothelial cancer, gastric cancer, cholangiocarcinoma, and lung cancer. It also has other pipeline product candidates. The company was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.